# Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

Study · id `cardio:ct-nct05347693` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05347693](<https://clinicaltrials.gov/study/NCT05347693>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05347693

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 186 participants.

## Technical summary

Registry record NCT05347693. Randomized; no masking; primary purpose treatment. Start 2022-03-24 (actual); primary completion 2024-12-10 (actual). Results posted on 2025-11-28.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 186 participants (enrolled count; ClinicalTrials.gov record NCT05347693, source copy `cardio:ctgov-nct05347693-2025-11-28`, retrieved 2026-10-26)
- Started: 2022-03-24 (actual) (ClinicalTrials.gov record NCT05347693, source copy `cardio:ctgov-nct05347693-2025-11-28`, retrieved 2026-10-26)
- Primary completion: 2024-12-10 (actual) (ClinicalTrials.gov record NCT05347693, source copy `cardio:ctgov-nct05347693-2025-11-28`, retrieved 2026-10-26)
- Completion: 2024-12-10 (actual) (ClinicalTrials.gov record NCT05347693, source copy `cardio:ctgov-nct05347693-2025-11-28`, retrieved 2026-10-26)
- Results first posted: 2025-11-28 (ClinicalTrials.gov record NCT05347693, source copy `cardio:ctgov-nct05347693-2025-11-28`, retrieved 2026-10-26)
- Countries: Belgium; France; Italy; Netherlands; Spain; United Kingdom (ClinicalTrials.gov record NCT05347693, source copy `cardio:ctgov-nct05347693-2025-11-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05347693-2025-11-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
- Acronym: CONTINUITY
- Condition: Hyperkalaemia
- Condition: Chronic Kidney Disease
- Intervention (Drug): Sodium Zirconium Cyclosilicate (SZC)
- Intervention (Drug): Local standard of care
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: e7b9a40c8e4d970edcb3e3b83921aa6fc06eba66161b80f0c42d432827c774ef
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
